Loading clinical trials...
Loading clinical trials...
A Phase 3, Open Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661 in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous or Heterozygous for the F508del CFTR Mutation
Conditions
Interventions
TEZ
TEZ/IVA
+1 more
Locations
33
United States
Birmingham, Alabama, United States
Anchorage, Alaska, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
Palo Alto, California, United States
Aurora, Colorado, United States
Start Date
November 1, 2016
Primary Completion Date
September 1, 2018
Completion Date
September 1, 2018
Last Updated
March 4, 2020
NCT04469439
NCT04530383
NCT06154447
NCT05422222
NCT06984679
NCT02417740
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions